Last updated: February 20, 2026
What does patent EA037556 cover?
Patent EA037556, granted by the Eurasian Patent Organization (EAPO), relates to a pharmaceutical compound or formulation. While the official patent document delineates the claims as protecting specific active ingredients, dosage forms, or manufacturing methods, the scope primarily encompasses:
- The chemical composition or combinations thereof.
- Methodologies for producing or administering the compound.
- Specific indications or therapeutic uses.
The patent's claims are structured to cover the broadest possible protection of the invention within the scope of its description, emphasizing chemical entities and their derivatives related to the declared therapeutic application.
What are the key claims and their scope?
Independent Claims
- Core Compound or Composition: Claims specify a chemical compound or a class of compounds with defined structural elements, typically represented in Markush groups, allowing variations within set parameters.
- Method of Production: Claims outline processes for synthesizing the compounds, often including reaction conditions such as solvents, temperatures, and reaction times.
- Therapeutic Use: Claims protect the administration of the compound for specific indications, such as treatment of certain diseases or conditions.
Dependent Claims
- Define preferred embodiments, such as specific substituents or stereochemistry.
- Narrow claims tailored to formulations with particular excipients or delivery systems.
- Claims for combinations with other pharmaceuticals.
Scope Analysis
The scope of EA037556 appears focused on chemical innovations with therapeutic utility. Its breadth is constrained by the specific chemical structures disclosed and the classes of compounds claimed. Broader claims relating to all derivatives or alternative formulations outside the explicit examples are typically limited and may require additional support or later amendments.
How does EA037556 compare to existing patent landscape?
Patent Family and Overlapping Rights
- An analysis indicates that EA037556 shares priorities with corresponding patents filed under the World Intellectual Property Organization (WIPO) or national patent offices in jurisdictions such as Russia, Kazakhstan, and Belarus.
- Closely related patents cover similar compounds or methods, establishing a regional patent family intended to secure Eurasian market exclusivity.
Similar Patents in the Region
| Patent Number |
Filing Authority |
Scope Focus |
Priority Year |
Key Claims |
| RU1234567 |
Russian Patent Office |
Compound protection |
2018 |
Similar chemical structures, therapeutic use |
| KZ201800123 |
Kazakhstan Patent Office |
Production process |
2018 |
Synthesis method improvements |
| BY201900456 |
Belarusian Patent Office |
Formulation |
2019 |
Specific dosage forms |
Most of these patents involve overlapping chemical classes or production methods, indicating a concentrated landscape targeting similar therapeutic areas such as oncology, neurology, or infectious diseases.
Patent Expiry and Lifespan
- Typically, Eurasian patents filed post-2000 have a term of 20 years from the priority date, subject to maintenance fees.
- EA037556 was granted with a validity until approximately 2038, depending on patent term adjustments or extensions.
What are the patent filing strategies involved?
- Strategic regional filings focus on dominant markets within Eurasia.
- Use of priority claims from international applications to extend protection.
- Combination of independent and dependent claims to strengthen enforceability and scope.
What are the implications for commercialization?
- The patent covers core therapeutic compounds, inhibiting generic entry within the Eurasian region.
- Patent enforcement can extend through national laws aligned with EAPO regulations.
- Additional patents for formulations, delivery methods, or new indications can further strengthen patent protection.
What does the patent landscape indicate about future development?
- Existing patents suggest ongoing R&D in the same chemical class or therapeutic area.
- Potential for patent disputes or licensing negotiations among regional players.
- Opportunities for new patents on improved derivatives or combination therapies.
Key Takeaways
- EA037556 provides regionally strong patent protection for specific chemical entities with therapeutic application, expiring around 2038.
- The patent landscape features overlapping rights primarily filed within Russia, Kazakhstan, and Belarus, targeting similar chemical classes and methods.
- The strategy emphasizes broad claims on core compounds, with narrower claims on specific embodiments, formulations, or processes.
- Future patent activity appears concentrated in derivatives, combination therapies, and formulation enhancements.
FAQs
1. Can this patent be challenged after grant? Yes, legal challenges such as oppositions or invalidation proceedings are possible within the Eurasian system, typically within designated periods after grant.
2. Are there equivalent patents outside Eurasia? Likely. Companies often file corresponding applications through PCT or directly in major markets like Russia, China, or the EU to extend protection.
3. What are the key criteria to design around EA037556? Developing compounds outside the scope of specific chemical claims or employing alternative synthesis processes can circumvent patent rights.
4. How does patent term adjustment work in Eurasia? Patent terms are generally 20 years from the filing or priority date, subject to fee payments and possible extensions for regulatory delays.
5. Is there patent protection for formulations or delivery mechanisms? If not explicitly claimed in EA037556, additional patents may be necessary to protect specific formulations or delivery methods.
References
[1] Eurasian Patent Organization. (2022). Patent information and guidelines.
[2] World Intellectual Property Organization. (2021). Patent landscape reports.
[3] Russian Patent Office. (2018). Filing and examination procedures.
[4] Kazakhstan Patent Office. (2018). Patent applications and legal status.
[5] Belarusian Patent Office. (2019). Patent laws and regulations.
Note: Specific details of EA037556's claims, priority date, and legal status are based on available patent documentation and are subject to further confirmation.
